Ototoxicity associated with high-dose carboplatin for patients with previously treated germ cell tumors.
cancer treatment
germ cell tumor
hearing loss
high-dose carboplatin
ototoxicity
survivorship
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
16 Sep 2023
16 Sep 2023
Historique:
revised:
26
06
2023
received:
28
03
2023
accepted:
18
07
2023
medline:
16
9
2023
pubmed:
16
9
2023
entrez:
16
9
2023
Statut:
aheadofprint
Résumé
High-dose carboplatin is an essential part of curative high-dose chemotherapy (HDCT) for patients with previously treated germ cell tumors (GCTs). Although hearing loss (HL) is a known side effect of HDCT, data on its severity and characteristics are limited. Eligible patients received HDCT for GCTs from 1993 to 2017 and had audiograms before and after HDCT. HL severity was classified by American Speech-Language-Hearing Association criteria, and mean change in hearing threshold at each frequency (0.25-8 kHz) was estimated from pre- to post-HDCT and between HDCT cycles. Of 115 patients (median age, 32 years), 102 (89%) received three cycles of HDCT. Of 106 patients with normal hearing to mild HL in the speech frequencies (0.5-4 kHz) before HDCT, 70 (66%) developed moderate to profound HL in the speech frequencies after HDCT. Twenty-five patients (22%) were recommended for hearing aids after HDCT. Patients with moderate to profound HL isolated to the higher frequencies (6-8 kHz) before HDCT were more likely to develop moderate to profound HL in the speech frequencies after HDCT (94% vs. 61%; p = .01) and to be recommended for hearing aids (39% vs. 18%; p = .05). HL was frequent after HDCT for GCTs, with most patients developing at least moderate HL in the speech frequencies and approximately one in five recommended for hearing aids. Moderate to profound HL isolated to high frequencies at baseline was predictive of more clinically significant hearing impairment after HDCT. Some patients with germ cell tumors, the most common malignancy in adolescent and young adult men, are not cured with standard-dose chemotherapy and require high-dose chemotherapy (HDCT). Using detailed hearing assessments of patients receiving HDCT, we found that most patients developed significant hearing loss and that one in five needed hearing aids. Thus, strategies to reduce this side effect are urgently needed, and all patients receiving HDCT should have a hearing test after therapy.
Sections du résumé
BACKGROUND
BACKGROUND
High-dose carboplatin is an essential part of curative high-dose chemotherapy (HDCT) for patients with previously treated germ cell tumors (GCTs). Although hearing loss (HL) is a known side effect of HDCT, data on its severity and characteristics are limited.
METHODS
METHODS
Eligible patients received HDCT for GCTs from 1993 to 2017 and had audiograms before and after HDCT. HL severity was classified by American Speech-Language-Hearing Association criteria, and mean change in hearing threshold at each frequency (0.25-8 kHz) was estimated from pre- to post-HDCT and between HDCT cycles.
RESULTS
RESULTS
Of 115 patients (median age, 32 years), 102 (89%) received three cycles of HDCT. Of 106 patients with normal hearing to mild HL in the speech frequencies (0.5-4 kHz) before HDCT, 70 (66%) developed moderate to profound HL in the speech frequencies after HDCT. Twenty-five patients (22%) were recommended for hearing aids after HDCT. Patients with moderate to profound HL isolated to the higher frequencies (6-8 kHz) before HDCT were more likely to develop moderate to profound HL in the speech frequencies after HDCT (94% vs. 61%; p = .01) and to be recommended for hearing aids (39% vs. 18%; p = .05).
CONCLUSIONS
CONCLUSIONS
HL was frequent after HDCT for GCTs, with most patients developing at least moderate HL in the speech frequencies and approximately one in five recommended for hearing aids. Moderate to profound HL isolated to high frequencies at baseline was predictive of more clinically significant hearing impairment after HDCT.
PLAIN LANGUAGE SUMMARY
CONCLUSIONS
Some patients with germ cell tumors, the most common malignancy in adolescent and young adult men, are not cured with standard-dose chemotherapy and require high-dose chemotherapy (HDCT). Using detailed hearing assessments of patients receiving HDCT, we found that most patients developed significant hearing loss and that one in five needed hearing aids. Thus, strategies to reduce this side effect are urgently needed, and all patients receiving HDCT should have a hearing test after therapy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R25CA020449
Pays : United States
Informations de copyright
© 2023 American Cancer Society.
Références
Nigam M, Aschebrook-Kilfoy B, Shikanov S, Eggener S. Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol. 2014;33(5):623-631. doi:10.1007/s00345-014-1361-y
Dieckmann K-P, Pichlmeier U. Clinical epidemiology of testicular germ cell tumors. World J Urol. 2004;22(1):2-14. doi:10.1007/s00345-004-0398-8
Wilkinson PM, Read G. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997;15(2):594-603.
Beyer J, Collette L, Sauvé N, et al. Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-Update Consortium. J Clin Oncol. 2021;39(14):1553-1562. doi:10.1200/jco.20.03292
Gillessen S, Sauvé N, Collette L, et al. Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG Update Consortium. J Clin Oncol. 2021;39(14):1563-1574. doi:10.1200/jco.20.03296
Feldman DR, Huddart R, Hall E, Beyer J, Powles T. Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER trial. J Cancer. 2011;2:374-377. doi:10.7150/jca.2.374
Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007;357(4):340-348. doi:10.1056/nejmoa067749
Adra N, Abonour R, Althouse SK, Albany C, Hanna NH, Einhorn LH. High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: the Indiana University experience. J Clin Oncol. 2017;35(10):1096-1102. doi:10.1200/jco.2016.69.5395
Motzer RJ, Mazumdar M, Sheinfeld J, et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol. 2000;18(6):1173-1180. doi:10.1200/jco.2000.18.6.1173
Kondagunta GV, Bacik J, Sheinfeld J, et al. Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol. 2006;25(1):85-90. doi:10.1200/jco.2006.06.9401
Feldman DR, Sheinfeld J, Bajorin DF, et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol. 2010;28(10):1706-1713. doi:10.1200/jco.2009.25.1561
Lorch A, Kollmannsberger C, Hartmann JT, et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Orthod. 2007;25(19):2778-2784. doi:10.1200/jco.2006.09.2148
Lorch A, Kleinhans A, Kramar A, et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol. 2012;30(8):800-805. doi:10.1200/jco.2011.38.6391
van Warmerdam LJ, Rodenhuis S, van der Wall E, Maes R, Beijnen J. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support. Br J Cancer. 1996;73(8):979-984. doi:10.1038/bjc.1996.191
Parsons SK, Neault MW, Lehmann LE, et al. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant. 1998;22(7):669-674. doi:10.1038/sj.bmt.1701391
Qaddoumi I, Bass JK, Wu J, et al. Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol. 2012;30(10):1034-1041. doi:10.1200/jco.2011.36.9744
Dubs A, Jacky E, Stahel R, Taverna C, Honegger H. Ototoxicity in patients with dose-intensive therapy for cisplatin-resistant germ cell tumors. J Clin Oncol. 2004;22(6):1158. doi:10.1200/jco.2004.99.239
Chevreau C, Thomas F, Couteau C, Dalenc F, Mourey L, Chatelut E. Ototoxicity of high-dose carboplatin. J Clin Oncol. 2005;23(15):3649-3650. doi:10.1200/jco.2005.05.348
Feldman DR, Glezerman I, Patil S, et al. Phase I/II trial of paclitaxel with ifosfamide followed by high-dose paclitaxel, ifosfamide, and carboplatin (TI-TIC) with autologous stem cell reinfusion for salvage treatment of germ cell tumors. Clin Genitourin Cancer. 2015;13(5):453-460. doi:10.1016/j.clgc.2015.05.003
Huth ME, Ricci AJ, Cheng AG. Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryngol. 2011;2011:937861. doi:10.1155/2011/937861
Degree of Hearing Loss. American Speech-Language-Hearing Association. Accessed April 26, 2022. https://www.asha.org/practice-portal/clinical-topics/hearing-loss/
Olsen WO, Markin ND. Speech audiometry. In: Rintelman W, ed. Hearing and Assessment.University Park Press; 1979:133-206.
Frisina RD, Wheeler HE, Fossa SD, et al. Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol. 2016;34(23):2712-2720. doi:10.1200/jco.2016.66.8822
Khan A, Mubdi N, Budnick A, et al. The experience of hearing loss in adult survivors of childhood and young adult cancer: a qualitative study. Cancer. 2020;126(8):1776-1783. doi:10.1002/cncr.32698
Sanchez VA, Shuey MM, Dinh PC, et al. Patient-reported functional impairment due to hearing loss and tinnitus after cisplatin-based chemotherapy. J Clin Oncol. 2023;41(12):2211-2226. doi:10.1200/jco.22.01456
Moeung S, Chevreau C, Broutin S, et al. Therapeutic drug monitoring of carboplatin in high-dose protocol (TI-CE) for advanced germ cell tumors: pharmacokinetic results of a phase II multicenter study. Clin Cancer Res. 2017;23:7171-7179. doi:10.1158/1078-0432.ccr-17-1344
Chevreau C, Massard C, Flechon A, et al. Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors. Cancer Med. 2021;10(7):2250-2258. doi:10.1002/cam4.3687
Brock PR, Maibach R, Childs M, et al. Sodium thiosulfate for protection from cisplatin-induced hearing loss. N Engl J Med. 2018;378(25):2376-2385. doi:10.1056/nejmoa1801109
Freyer DR, Chen L, Krailo MD, et al. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18(1):63-74. doi:10.1016/s1470-2045(16)30625-8
Doolittle ND, Muldoon LL, Brummett RE, et al. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res. 2001;7:493-500.
Neuwelt EA, Brummett RE, Doolittle ND, et al. First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate. J Pharmacol Exp Ther. 1998;286(1):77-84.
Neuwelt EA, Brummett RE, Remsen LG, et al. In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity. Cancer Res. 1996;56:706-709.
Viglietta V, Shi F, Hu Q-Y, et al. Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients. Invest New Drugs. 2020;38(5):1463-1471. doi:10.1007/s10637-020-00918-1
Rybak LP, Dhukhwa A, Mukherjea D, Ramkumar V. Local drug delivery for prevention of hearing loss. Front Cell Neurosci. 2019;13:300. doi:10.3389/fncel.2019.00300
Liu SS, Yang R. Inner ear drug delivery for sensorineural hearing loss: current challenges and opportunities. Front Neurosci. 2022;16:867453. doi:10.3389/fnins.2022.867453
Rischin D, O’Leary SJ, Hart CD, et al. A phase 1 clinical trial of DB-020 intratympanic injections administered prior to high dose cisplatin chemotherapy to reduce ototoxicity. J Clin Orthod. 2023;41(16)(suppl):6043. doi:10.1200/jco.2023.41.16_suppl.6043
Beyea JA, Lau C, Cooke B, Hall S, Nathan PC, Gupta S. Long-term incidence and predictors of significant hearing loss requiring hearing assistive devices among childhood cancer survivors: a population-based study. J Clin Oncol. 2020;38(23):2639-2646. doi:10.1200/jco.19.03166
Soliman SE, D’Silva CN, Dimaras H, Dzneladze I, Chan H, Gallie BL. Clinical and genetic associations for carboplatin-related ototoxicity in children treated for retinoblastoma: a retrospective noncomparative single-institute experience. Pediatr Blood Cancer. 2018;65(5):e26931. doi:10.1002/pbc.26931
Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer. 2004;40(16):2445-2451. doi:10.1016/j.ejca.2003.08.009
Sanchez VA, Dinh PC, Rooker J, et al. Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy. J Cancer Surviv. 2023;17(1):27-39. doi:10.1007/s11764-022-01313-w
Oldenburg J, Fosså SD, Ikdahl T. Genetic variants associated with cisplatin-induced ototoxicity. Pharmacogenomics. 2008;9(10):1521-1530. doi:10.2217/14622416.9.10.1521
Trendowski MR, El Charif O, Dinh PC, Travis LB, Dolan ME. Genetic and modifiable risk factors contributing to cisplatin-induced toxicities. Clin Cancer Res. 2019;25(4):1147-1155. doi:10.1158/1078-0432.ccr-18-2244
Ross CJD, Katzov-Eckert H, Dubé M-P, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet. 2009;41(12):1345-1349. doi:10.1038/ng.478
Pussegoda K, Ross CJ, Visscher H, et al. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther. 2013;94(2):243-251. doi:10.1038/clpt.2013.80
Knight KR, Kraemer DF, Winter C, Neuwelt EA. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol. 2007;25(10):1190-1195. doi:10.1200/jco.2006.07.9723